ヒト絨毛性ゴナドトロピン市場：製品、治療領域、エンドユーザー別-2025-2030年世界予測

ヒト絨毛性ゴナドトロピン市場は、2023年に12億7,000万米ドルと評価され、2024年には13億7,000万米ドルに達すると予測され、CAGR 7.53％で成長し、2030年には21億1,000万米ドルになると予測されています。

ヒト絨毛性ゴナドトロピン（HCG）は胎盤によって妊娠中に産生されるホルモンで、胎児の発育に重要な役割を果たします。市場調査の文脈では、HCGは不妊治療、体重管理治療、妊娠検査における診断用途での商業的応用が観察されます。HCGの必要性は、主に体外受精（IVF）のような生殖補助医療（ART）での使用を通じて、生殖の健康を補助する用途にかかっています。HCGの医療用途は不妊治療にとどまらず、特定のがん種に存在することから腫瘍の検出や管理といった分野でも調査されています。最終用途の範囲には、不妊治療クリニック、研究所、製薬会社、診断センターが含まれます。

HCG市場に影響を与える主な成長要因としては、不妊症の有病率の増加、生殖に関する健康意識の高まり、革新的な治療オプションを促進するバイオテクノロジーの進歩などが挙げられます。さらに、迅速診断キットに対する需要の高まりも市場を後押ししています。HCGの腫瘍学への応用範囲を拡大し、体重管理に対応する製剤を開発することで、治療法開発の流れが開ける可能性があります。しかし、規制上のハードル、倫理的配慮、不妊治療の高コストといった課題が大きな制約となり、市場の成長を抑制する可能性があります。不妊治療につきまとうスティグマを含む社会文化的要因も、市場導入に水を差す可能性があります。

技術革新と事業成長のためには、精密医療とHCGの生化学的経路の研究に注力し、その治療用途を拡大することが、市場の実行可能性を高める可能性があります。さらに、費用対効果の高い治療手法に投資し、バイオテクノロジー企業、研究機関、ヘルスケアプロバイダー間の強力な協力ネットワークを確立することで、市場浸透を拡大することができます。HCG市場の性質はダイナミックであり、遺伝子研究やバイオ製造における革新が潜在的な進化のきっかけとなります。消費者のニーズを理解し、新たなバイオテクノロジーを活用し、倫理的な透明性を醸成することで、市場関係者を持続的成長と競争優位へと導くことができます。

市場力学：急速に進化するヒト絨毛性ゴナドトロピン市場における重要な市場洞察の解明

ヒト絨毛性ゴナドトロピン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 不妊人口の増加
  • 不妊治療クリニック開発への投資の増加
  • 不妊治療に対する意識の高まり
• 市場抑制要因
  • ヒト絨毛性ゴナドトロピン治療に伴う高コスト
• 市場機会
  • 遺伝子組換え技術の進歩
  • ヘルスケア分野におけるゴナドトロピン療法の登場
• 市場の課題
  • ヒト絨毛性ゴナドトロピン療法の副作用の可能性

ポーターのファイブフォース：ヒト絨毛性ゴナドトロピン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、ヒト絨毛性ゴナドトロピン市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ヒト絨毛性ゴナドトロピン市場における外部からの影響の把握

外部マクロ環境要因は、ヒト絨毛性ゴナドトロピン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ヒト絨毛性ゴナドトロピン市場における競合情勢の把握

ヒト絨毛性ゴナドトロピン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスヒト絨毛性ゴナドトロピン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ヒト絨毛性ゴナドトロピン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ヒト絨毛性ゴナドトロピン市場における成功への道筋を描く

ヒト絨毛性ゴナドトロピン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 人口における不妊症の増加
    • 不妊治療クリニックの開発への投資増加
    • 不妊治療に対する意識の向上
  • 抑制要因
    • ヒト絨毛性ゴナドトロピン療法に伴う高額な費用
  • 機会
    • 組み換え技術の進歩
    • ヘルスケア分野におけるゴナドトロピン療法の出現
  • 課題
    • ヒト絨毛性ゴナドトロピン療法の副作用の可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ヒト絨毛性ゴナドトロピン市場：製品別

• 天然抽出
• 組み換え

第7章 ヒト絨毛性ゴナドトロピン市場治療領域別

• 女性不妊治療
• 男性性腺機能低下症
• 精子減少症の治療

第8章 ヒト絨毛性ゴナドトロピン市場：エンドユーザー別

• 不妊治療クリニック
• 調査機関

第9章 南北アメリカのヒト絨毛性ゴナドトロピン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のヒト絨毛性ゴナドトロピン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのヒト絨毛性ゴナドトロピン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Biocare Medical, LLC
• Bristol Myers Squibb Company
• Cipla Limited
• Ferring B.V.
• Fresenius Kabi AG
• Intas Pharmaceuticals Ltd.
• Kamia Biomedical Company
• Lee Biosolutions, Inc.
• Life Medicare & Biotech Private Limited
• Livzon Pharmaceutical Group Inc.
• Lupin Limited
• Merck & Co., Inc.
• Prospec-Tany Technogene Ltd.
• Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
• Sanzyme（P）Ltd.
• Scripps Laboratories, Inc.
• Sun Pharmaceutical Industries Ltd.
• Sunrise International Labs Ltd.

LIST OF FIGURES

• FIGURE 1. HUMAN CHORIONIC GONADOTROPIN MARKET RESEARCH PROCESS
• FIGURE 2. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HUMAN CHORIONIC GONADOTROPIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HUMAN CHORIONIC GONADOTROPIN MARKET DYNAMICS
• TABLE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY NATURALLY EXTRACTED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FEMALE INFERTILITY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY MALE HYPOGONADISM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY OLIGOSPERMIA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 29. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 46. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 49. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 101. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 113. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 116. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 145. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023

The Human Chorionic Gonadotropin Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.37 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 2.11 billion by 2030.

Human Chorionic Gonadotropin (HCG) is a hormone produced during pregnancy by the placenta, playing a critical role in fetal development. In the market research context, HCG is observed for its commercial applications in fertility treatments, weight management therapies, and its diagnostic use in pregnancy tests. The necessity for HCG hinges on its application in assisting reproductive health, primarily through its use in assisted reproductive technologies (ART) like in-vitro fertilization (IVF). Its medical applications extend beyond fertility, as it's being researched in areas such as tumor detection and management due to its presence in certain cancer types. The end-use scope covers fertility clinics, research laboratories, pharmaceutical companies, and diagnostic centers.

Key growth factors influencing the HCG market include the increasing prevalence of infertility, rising awareness regarding reproductive health, and advancements in biotechnology facilitating innovative treatment options. Additionally, the market is propelled by the growing demand for rapid diagnostic kits. A potential opportunity lies in expanding the scope of HCG applications in oncology and developing its formulations to address weight management, opening streams for therapeutic developments. However, challenges such as regulatory hurdles, ethical considerations, and the high cost of fertility treatments pose significant limitations, potentially restraining market growth. Even socio-cultural factors, including the stigma attached to fertility treatments, could dampen market adoption.

For innovation and business growth, focusing on research in precision medicine and the biochemical pathways of HCG to broaden its therapeutic applications could enhance market viability. Moreover, investing in cost-effective treatment methodologies and establishing strong collaborative networks among biotech firms, research institutes, and healthcare providers can extend market penetration. The nature of the HCG market is dynamic, with innovations in genetic research and biomanufacturing catalyzing potential evolution. Understanding consumer needs, leveraging emerging biotechnologies, and fostering ethical transparency can guide market actors towards sustainable growth and competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Chorionic Gonadotropin Market

The Human Chorionic Gonadotropin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidents of infertility among populations
  • Growing investments in the development of fertility clinics
  • Increasing awareness of fertility treatments
• Market Restraints
  • High cost associated with human chorionic gonadotropin therapy
• Market Opportunities
  • Advancements in recombinant technology
  • Emergence of gonadotropin therapy in the healthcare sector
• Market Challenges
  • Possible side effects of human chorionic gonadotropin therapy

Porter's Five Forces: A Strategic Tool for Navigating the Human Chorionic Gonadotropin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Chorionic Gonadotropin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Chorionic Gonadotropin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Chorionic Gonadotropin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Chorionic Gonadotropin Market

A detailed market share analysis in the Human Chorionic Gonadotropin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Chorionic Gonadotropin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Chorionic Gonadotropin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Chorionic Gonadotropin Market

A strategic analysis of the Human Chorionic Gonadotropin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Chorionic Gonadotropin Market, highlighting leading vendors and their innovative profiles. These include Biocare Medical, LLC, Bristol Myers Squibb Company, Cipla Limited, Ferring B.V., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Kamia Biomedical Company, Lee Biosolutions, Inc., Life Medicare & Biotech Private Limited, Livzon Pharmaceutical Group Inc., Lupin Limited, Merck & Co., Inc., Prospec-Tany Technogene Ltd., Qingdao kangyuan Biopharmaceutical Group Co., Ltd., Sanzyme ( P ) Ltd., Scripps Laboratories, Inc., Sun Pharmaceutical Industries Ltd., and Sunrise International Labs Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Chorionic Gonadotropin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Naturally Extracted and Recombinant.
• Based on Therapeutic Area, market is studied across Female Infertility Treatment, Male Hypogonadism, and Oligospermia Treatment.
• Based on End-User, market is studied across Fertility Clinics and Research Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidents of infertility among populations
    • 5.1.1.2. Growing investments in the development of fertility clinics
    • 5.1.1.3. Increasing awareness of fertility treatments
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with human chorionic gonadotropin therapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in recombinant technology
    • 5.1.3.2. Emergence of gonadotropin therapy in the healthcare sector
  • 5.1.4. Challenges
    • 5.1.4.1. Possible side effects of human chorionic gonadotropin therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Human Chorionic Gonadotropin Market, by Product

• 6.1. Introduction
• 6.2. Naturally Extracted
• 6.3. Recombinant

7. Human Chorionic Gonadotropin Market, by Therapeutic Area

• 7.1. Introduction
• 7.2. Female Infertility Treatment
• 7.3. Male Hypogonadism
• 7.4. Oligospermia Treatment

8. Human Chorionic Gonadotropin Market, by End-User

• 8.1. Introduction
• 8.2. Fertility Clinics
• 8.3. Research Institutions

9. Americas Human Chorionic Gonadotropin Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Human Chorionic Gonadotropin Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Human Chorionic Gonadotropin Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Biocare Medical, LLC
• 2. Bristol Myers Squibb Company
• 3. Cipla Limited
• 4. Ferring B.V.
• 5. Fresenius Kabi AG
• 6. Intas Pharmaceuticals Ltd.
• 7. Kamia Biomedical Company
• 8. Lee Biosolutions, Inc.
• 9. Life Medicare & Biotech Private Limited
• 10. Livzon Pharmaceutical Group Inc.
• 11. Lupin Limited
• 12. Merck & Co., Inc.
• 13. Prospec-Tany Technogene Ltd.
• 14. Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
• 15. Sanzyme ( P ) Ltd.
• 16. Scripps Laboratories, Inc.
• 17. Sun Pharmaceutical Industries Ltd.
• 18. Sunrise International Labs Ltd.